Natural history of Type 2 and 3 spinal muscular atrophy: 2-year NatHis-SMA study.
Mélanie AnnoussamyAndreea M SeferianAurore DaronYann PéréonClaude CancesCarole VuillerotLiesbeth De WaeleVincent LaugelUlrike ScharaTeresa GidaroCharlotte LilienJean-Yves HogrelPierre CarlierEmmanuel FournierLinda LowesKsenija GorniMyriam Ly-Le MoalNicole HellbachTimothy SeabrookChristian CzechRicardo HermosillaLaurent Servaisnull nullPublished in: Annals of clinical and translational neurology (2020)
These data demonstrate that the MFM32, MyoGrip, MyoPinch, and ActiMyo® enable the detection of a significant decline in patients with Type 2 and 3 SMA over 12 or 24 months.